In our previous studies using HER2-specific vaccines, an oncogenic driver for HER2+ breast cancer, we found that targeting this gene and signaling axis conferred significant anti-tumor efficacy and inhibition of tumor growth, while vaccination against a non-oncogenic tumor-associated antigen (EGFP), showed no effect on tumor growth despite potent antigen-specific immunity against EGFP [15]. This evidence concerns the gene ERBB2 and breast cancer.